Compare Ginkgo Bioworks Holdings Inc (DNA) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Plby Group Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.3 (market cap $505.73M), while Plby Group Inc trades at $1.26 (market cap $162.94M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 3.1× Plby Group Inc's market cap. Which is the better fit depends on your goals.
| DNA | PLBY | |
|---|---|---|
Market Cap | $505.73M | $162.94M |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $2.71 |
52-Week Low | $5.48 | $1.11 |
Enterprise Value | $607.68M | $308.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
PLBY trades at $1.28, up 8.47% in the last session, with a bullish technical signal from moving averages. The company shows improving fundamentals, with Q2 2026 revenue growth and a return to operating profitability, while net income margin remains slim at 0.23%. Recent news highlights inclusion in the Russell 2000 index and a share repurchase program.
The outlook is cautiously optimistic, supported by analyst consensus and positive cash flow trends, but high debt levels and inconsistent earnings history pose risks. Investment opportunity lies in brand licensing growth, while execution and competitive pressures are key watchpoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
